Nanobiotix Files September 2025 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1760854
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, disclosure
TL;DR
Nanobiotix filed its monthly 6-K report, confirming its status as a foreign private issuer and its use of Form 20-F for annual reports.
AI Summary
Nanobiotix S.A. filed a Form 6-K on September 30, 2025, for the month of September 2025. The filing is a report of a foreign private issuer and indicates that the company files annual reports under cover of Form 20-F. The company's principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.
Why It Matters
This filing provides routine disclosure for Nanobiotix S.A. as a foreign private issuer, informing investors about its reporting status and administrative details.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the report
- 60 Rue de Wattignies, 75012 Paris, France (location) — Principal executive office address
FAQ
What type of filing is Nanobiotix S.A. submitting?
Nanobiotix S.A. is submitting a Form 6-K, which is a Report of Foreign Private Issuer.
What period does this Form 6-K cover?
This Form 6-K is for the month of September 2025.
Does Nanobiotix S.A. file annual reports under Form 20-F or 40-F?
Nanobiotix S.A. indicates that it files annual reports under cover of Form 20-F.
Where is Nanobiotix S.A.'s principal executive office located?
The principal executive office of Nanobiotix S.A. is located at 60 Rue de Wattignies, 75012 Paris, France.
What is the Commission File Number for Nanobiotix S.A.?
The Commission File Number for Nanobiotix S.A. is 001-39777.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-09-29 18:30:03
Filing Documents
- f6k_092925.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 17KB
- 0001171843-25-006152.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: September 29, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer